Long-lasting, targeted control over coagulation disorders powered by RNA technology
About us
SeraGene Therapeutics is a pre-clinical stage biotech company committed to reimagining the treatment of coagulation disorders through innovative RNA and nanomedicine technologies.
Our vision
Patients on life-long treatments deserve a life well-lived. We envision a future where coagulation disorders can be effectively managed with low treatment burden therapies.
.svg)
Our technology
We are addressing limitations in current care standards for coagulation disorders by delivering innovative therapies that provide long-lasting control over disordered coagulation. Designed with life-long use in mind, we have selected high efficacy targets with a lower potential safety risk to meaningfully improve the quality of life for those living with coagulation disorders.
Our technology provides proprietary RNA agents with liver-targeting drug delivery vehicles to restore hemostasis by precisely modulating the endogenous expression of clotting proteins in the blood.
Our diverse portfolio of targets and technologies offer a suite of novel approaches for addressing the complex drivers of coagulation. We have eight patented assets in development ranging from discovery to late preclinical phase.
Our portfolio
Leveraging our expertise in coagulation biology and RNA technology, we hope to impact change in three key areas.
1
Developing innovative prophylactic therapies for rare bleeding disorders to provide effective treatment options that enhance patients’ quality of life.
2
Enhancing transfusable platelets for individuals with inherited or acquired platelet dysfunction.
3
Developing short and long-term prophylactic therapies for thrombotic disorders to manage thrombosis effectively while minimizing side effects.
Developing innovative prophylactic therapies for rare bleeding disorders to provide effective treatment options that enhance patients’ quality of life
Enhancing the stability and therapeutic functionality of transfusable platelets for individuals with inherited or acquired platelet dysfunction
Developing short and long-term prophylactic therapies for thrombotic disorders to manage thrombosis effectively while minimizing side effects
Preclinical data in large-animal disease models have shown promising outcomes for two lead assets, indicating their potential as first-in-class or best-in-class therapies for addressing coagulation disorders.
SeraGene has a vested interest in developing solutions for women and girls with bleeding disorders who are disproportionately burdened by uncontrolled bleeding.
Partner with us
Help us enable a life well-lived for patients with coagulation disorders.